SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Reducing the dose of medicine. Splitting the pills. Health care and medication. White medical pill broken into three pieces on blue background.
Regulatory
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to treat cerebral folate deficiency with “autistic features.”
April 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Finding Talent. Big Hands with Magnifying Glass Recruiting People. vector
Regulatory
FDA probes abortion pill anew after court keeps mail access alive
A Louisiana court on April 7 asked the FDA to complete its internal review of mifepristone’s safety and gave the agency six months to provide the court with an update on the investigation.
April 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Chemistry creative concept. Circle frame with icons. Flag of China
Manufacturing
Innovent’s CDMO gets green light to make biologics at large Chinese plant
The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial clients as it works to expand the plant’s capacity to 172,000 liters.
April 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Craftsmen are using silicone adhesives for general and industrial applications.
Deals
Roche sticks with C4T, adding up to $1B for molecular glue partnership
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
April 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Job Trends
Report: Biopharma Job Market Report Q1 2026
BioSpace’s Biopharma Job Market Report reveals early signs of recovery for 2026. A rise in job postings, a surge in contract roles and strong M&A and IPO activity point to future hiring growth and shifts in hiring strategy.
April 9, 2026
 · 
1 min read
 · 
BioSpace Insights
Japanese-style New Year's card template for the year of the snake1 (horizontal type) (without greeting text) Snake, Mt. Fuji, sunrise, clouds
Funding
Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.
April 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Business people and concepts vector art exit
Government
PhMRA’s long-standing leader Steve Ubl to leave lobby group by year-end
Industry leader Steve Ubl has served as PhRMA’s CEO for more than a decade, the longest tenure of any head of the trade group.
April 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Automation, Collaboration and the Future of Advanced Therapies
In this episode of Denatured, you’ll hear from Jason Jones, head of global business development at Cellular Origins and Alexander Seyf, founder & CEO of Autolomous. They discuss how the push to scale cell and gene therapy manufacturing is accelerating interest in automation, digitization, robotics and deeper collaboration across the ecosystem.
April 9, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Man in suit on a paper boat sailing through golden coins with dollar signs, paper collage style, on a textured purple background, symbolizing money journey
Mergers & acquisitions
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M&A pace. Executives detailed the rationale for buying Arcellx, Ouro Medicine and Tubulis GmbH and whether they are interested in further deals.
April 8, 2026
 · 
5 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS